<DOC>
	<DOCNO>NCT02199184</DOCNO>
	<brief_summary>The goal clinical research study learn add ofatumumab/rituximab standard combination DA-EPOCH ( dose-adjusted etoposide , prednisone , vincristine , cyclophosphamide ) help control disease patient newly diagnose relapsed/refractory Burkitt leukemia relapsed/refractory ALL . The safety drug combination also study .</brief_summary>
	<brief_title>Burkitt Leukemia - Dose-Adjusted Etoposide , Prednisone , Vincristine , Cyclophosphamide , Ofatumumab ( EPOCH - O )</brief_title>
	<detailed_description>Central Venous Catheter ( CVC ) : If find eligible take part study , receive CVC already one . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Study Drug Administration : Each cycle last 21-28 day . You receive 8 cycle EPOCH combination ofatumumab rituximab ( EPOCH-O/R ) 2 dos ofatumumab rituximab cycle first 4 cycle , except Cycle 1 , receive 1 extra dose ofatumumab help prevent side effect . You may receive rituximab instead ofatumumab insurance provider cover cost ofatumumab . You receive ofatumumab vein ( 2 hour ) Days 1 , 2 , 11 Cycle 1 . You also receive Days 1 8 Cycles 2 4 , Days 1 11 Cycle 3 . If receive rituximab instead ofatumumab , receive vein ( 2 hour ) Days 1 11 Cycles 1 3 Days 2 8 Cycles 2 4 . You receive etoposide , doxorubicin , vincristine vein 24 hour Days 1-4 cycle . You receive cyclophosphamide vein 1 2 hour Day 5 cycle . You take prednisone mouth 2 time day Days 1-5 cycle . You also receive pegfilgrastim vein within 3 day receive drug help prevent side effect . You may also receive filgrastim study doctor think need also help prevent side effect . If study doctor think need , receive methotrexate cytarabine spinal tap . The study doctor tell . You may able receive study drug clinic near home . Talk study doctor possible option . Study Visits : One ( 1 ) time week first cycle , every 2 week Cycles 2-8 , blood ( 2 tablespoon ) draw routine test . On Day 14 , 1-2 week later , every 3 month first year , every 6 month next 2 year : Â°You bone marrow aspiration and/or biopsy check status disease . Length Study : You may receive 8 cycle study drug . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow-Up Visits : One ( 1 ) time every 3 month first year finish receiving study drug every 6 month next 2 year , come clinic . The following test procedure perform : - Blood ( 2 tablespoon ) draw routine test . - You bone marrow aspiration and/or biopsy check status disease . Long-Term Follow-Up : The study staff call every 3 month 1 year finish receiving study drug . During call , ask feeling side effect may , drug may take . These call last 5 minute time . This investigational study . DA-EPOCH commercially available FDA-approved treatment Burkitt leukemia ALL . Ofatumumab rituximab commercially available FDA-approved treatment type chronic lymphocytic leukemia ( CLL ) . It consider investigational add ofatumumab DA-EPOCH treat Burkitt leukemia ALL . The study doctor explain study drug design work . Up 40 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Burkitt 's Burkittlike leukemia/lymphoma , either previously untreated , relapsed/refractory , HIVrelated . Patients HIV positive described report separately relapsed/refractory acute lymphoblastic leukemia ( ALL ) . 2 . All age eligible 3 . Zubrod performance status &lt; /= 3 ( ECOG Scale , Appendix E ) 4 . Adequate organ function creatinine less equal 2.0 mg/dL ( unless consider tumor relate ) , bilirubin less equal 2.0 mg/dL ( unless consider tumor relate ) . 5 . Adequate cardiac function define history clinically significant arrhythmia , history MI within 3 month prior study enrollment . Cardiac function assess history physical examination . 1 . Pregnant nursing woman . 2 . Active uncontrolled disease/infection judge treat physician 3 . Unable unwilling sign consent form 4 . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Burkitt leukemia</keyword>
	<keyword>Burkitt-like leukemia/lymphoma</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Relapsed/refractory</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Arzerra</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>DA-EPOCH</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Phone call</keyword>
</DOC>